A decade ago, patients with newly diagnosed multiple myeloma typically survived 3 to 5 years. However, the development of highly effective therapies — including proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies — has greatly improved outcomes. In addition to extending survival, these newer agents are associated with considerably less toxicity. “We not only have this...Continue Reading